Achalasia Cardia

Achalasia Cardia is a primary oesophageal motility disorder, characterised by a hypertensive lower oesophageal sphincter (LOS) which fails to relax on swallowing, and by aperistalsis of the body of the oesophagus.The aetiology of the disease remains unknown. Epidemiological findings rule out an infectious cause, and there appears to be minimal genetic influence. A viral cause is plausible but as of yet electron microscopy has failed to detect viral particles in the vagus nerve or in the oesophageal intramural nerve plexus. The incidence of the disease is 1-2 per 200,000 per year, with both sexes equally affected. Onset of the disease is typically between the ages of 20 and 50.

Achalasia Cardia

Inhomogeneous cardiac density: Not demonstrable in this presentation
Density crossing mid-line. Not demonstrable in this presentation
Right sided inlet to outlet shadow. Not demonstrable in this presentation
Barium swallow below: Dilated esophagus
The principal lesion is denervation of the oesophageal smooth muscle. While muscular abnormalities are also present, these appear to be secondary to the neural deficit. A decreased number of ganglion cells in the oesophageal intramural nerve plexus has been found in patients with achalasia, and the extent of this loss corresponds to the duration of the disease. There may also be degenerative changes in the vagus nerve, both in its branches to the oesophagus and in the dorsal motor nucleus. The interaction between nerve plexus and vagus nerve lesions is not yet clear. In both cases, the loss predominantly concerns inhibitory neurons. This would explain the increased basal LOS pressure as well as the inadequate sphincteric relaxation observed on swallowing. Degeneration of the oesophageal ganglion cells leads to permanent aperistalsis as the disease progresses and favours oesophageal dilatation.
Progressive dysphagia is the most common presenting symptom. It generally concerns both liquids and solids from the outset. The second most common symptom is the regurgitation of undigested food during or shortly after a meal. Approximately 36% of patients present with sub/retrosternal pain and a similar percentage with heartburn.11 Weight loss is a very common finding in patients with achalasia due to decreased food intake, and is a good indicator of the chronicity and severity of the condition. Patients may complain of nocturnal coughing if there is overspill of oesophageal contents into the trachea, which is increased in the supine position. Pulmonary infiltrates resulting from aspiration constitute a rare, but severe, complication.Diagnosis of achalasia cardia is based on history, barium swallow with fluoroscopy, upper endoscopy and oesophageal manometry.
Pseudoachalasia can occur in a number of conditions, most commonly in gastric adenocarcinoma.12 The mechanism may be infiltration of the oesophageal nerve plexus or constriction of the distal oesophagus by the tumour mass. Endoscopy can be used to rule out this differential diagnosis, which is more common among older patients, who usually present with marked weight loss. Oesophageal squamous cell carcinoma, lymphoma, lung carcinomas and a number of other malignancies can also cause pseudoachalasia. Other conditions which can mimic achalasia include Chaga’s disease, amyloidosis, sarcoidosis, oesophageal stricture, chronic idiopathic intestinal pseudo-obstruction and post-vagotomy disturbance.

TREATMENT

As the degenerative neural lesion of this disease cannot be corrected, treatment is directed at palliation of symptoms and prevention of complications. Effective peristalsis is rarely restored by successful treatment, but improved oesophageal emptying and a decrease in oesophageal diameter are generally expected. Four palliative treatments are available: pharmacotherapy, botulinum toxin injection, pneumatic dilatation and myotomy. They all aim to decrease LOS pressure and improve emptying by gravity.

Pharmacotherapy :

Smooth muscle relaxants alleviate symptoms and improve oesophageal emptying in up to 70% of patients. Nitrites, such as sublingual isosorbide dinitrite, and calcium channel blockers, such as diltiazem, nifedipine and verapamil, have this effect. The role of pharmacological agents in the long-term management of achalasia is unclear. It is not known whether their long-term use prevents dilatation and complications. This treatment option is suitable for patients with medical conditions that interfere with pneumatic dilatation or myotomy. Also, patients with severe weight loss can be treated pharmacologically until a healthy nutritional status can be re-established, making them better candidates for other forms of treatment.

Botulinum Toxin:

Botulinum toxin type A is derived from the controlled fermentation of Clostridium botulinum. The toxin binds to presynaptic cholinergic neuronal receptors, is internalised, and irreversibly interferes with acetylcholine release, probably by preventing the neurotransmitter vesicle docking and fusing with the axonal membrane. Pasricha and colleagues first demonstrated the similar ability of botulinum toxin to decrease LOS basal tone and improve symptoms in patients with achalasia. An initial, beneficial response at the level of the LOS occurs in 90% of patients, but symptoms reappear within a year in many initial responders.15 Side effects of this treatment are rare, but include chest discomfort for a few days after the injection and an occasional rash.
The best use of botulinum toxin injection in achalasia is still being explored, but this seemingly safe approach with little apparent morbidity may be of great advantage when a short-term treatment response is desired.

Dilatation:

Forceful dilatation of the gastroesophageal sphincter to a diameter of approximately 3 cm is necessary to tear the circular muscle and to ensure a lasting reduction in LOS pressure. Many types of dilators have been developed for this purpose, but it is pneumatic dilators which are conventionally used today. The technique of dilatation, inflation pressure and duration of inflation varies. Water-soluble contrast material is used to detect distal oesophageal leaks. Surgical consultation is undertaken if perforation is evident. Small perforations are managed conservatively with broad-spectrum antibiotics.16 Clinical deterioration e.g. shock, sepsis, haemorrhage or a finding of free-flowing barium into the mediastinum, requires immediate thoracotomy and repair.
At least 60% of patients have a good response and success rates exceeding 95% have been reported.17 The response rate varies with patient age, (younger patients do not do as well as older patients), and duration of symptoms, (those with a shorter history do not respond as well), but it does not seem to be related to the degree of oesophageal dilatation or tortuosity. The efficacy of this procedure is decreased by as much as half with each subsequent dilatation.
Morbidity is mostly related to oesophageal perforation, a complication in approximately 5% of patients, but surgical repair is required in less than half of these cases.17 Perforation may be more likely in severely malnourished patients, which raises the possibility that re-establishment of a good nutritional status decreases the complication rate following dilatation.

Surgery:

The goal of surgical therapy in achalasia is to decrease LOS resting pressure without completely compromising its competency against gastroesophageal reflux (GOR). The Heller procedure was described in 1913 and now a modification of this procedure is used most commonly in the surgical management of achalasia.19,20 An anterior myotomy is performed by dividing the circular muscle of the oesophagus down to the level of the mucosa. The myotomy extends less than 1cm onto the stomach and to several centimetres above the palpable region of the lower sphincter. The transthoracic approach is preferred, as it helps confirm the diagnosis, allows careful palpation and inspection of the oesophagus, and enables the surgeon to extend the myotomy proximally as far as is necessary. Open myotomies have good results in 80-90% of patients.21,22 They decrease the LOS pressure more reliably, and therefore have a greater efficacy than pneumatic dilatation.
Minimally invasive surgical procedures are becoming a preferable alternative to open myotomy, allowing the Heller myotomy to be performed thoracoscopically and laparoscopically .24,25,26 Shorter hospitalisation, less pain and early resumption of activity are the benefits of the minimally invasive approach, which remains as effective as the open techniques in the relief of dysphagia.27 Complications of minimally invasive surgery include: anterior gastric perforation, mucosal perforation at the gastroesophageal (GO) junction and, most significantly, GOR. Surgery is not necessary for a patient who has few symptoms and minimal oesophageal dilatation. It is, however, required for those with dilatation and food retention to prevent serious pulmonary complications and, of course, to provide symptomatic relief.

Pre-Operative Evaluation:

Symptomatic Evaluation

The severity of the symptoms is scored by the patient by questionnaire before and after surgery.

Barium Swallow

This should be the first test performed in the evaluation of dysphagia. It usually shows a “bird’s beak” narrowing at the GO junction and oesophageal dilatation proximal to the narrowing.

Endoscopy

Endoscopy should follow a barium swallow to rule out pseudoachalasia. It excludes gastroduodenal abnormalities, peptic malignancy and stricture.

Oesophageal Manometry

Typical manometrical findings are the absence of oesophageal peristalsis and a hypertensive LOS which fails to relax completely in response to swallowing.

Prolonged Ambulatory pH Monitoring

Prolonged pH monitoring is performed to determine if abnormal reflux is present. In patients who have a positive test result, it is essential to distinguish between true reflux and increased acidity due to stasis and fermentation.

Post-Operative Follow-Up

Patients are re-examined 2-6 weeks after surgery. Oesophageal manometry and pH monitoring are performed 2-3 months after the operation. Subsequently, patients are contacted for symptomatic evaluation.

Comparisons between therapies:

Pneumatic dilatation, pharmacotherapy and botulinum toxin injection are easy to use, usually well-tolerated and relatively cheap treatment options in achalasia. Surgery generally gives longer-lasting results as well as more complete relief of symptoms. Non-operative therapy is recommended initially. Patients are only referred for surgery if they remain symptomatic after 3 attempts at pneumatic dilatation.

Two studies done by Patti et al. (2001) and a study by Stewart et al. (1999 – comparing thoracoscopic to laparoscopic myotomies) indicate that laparoscopic myotomy is the superior approach, due shorter operative times and shorter duration of hospitalisation, as well as a more effective relief of dysphagia.28,29,30